Fate Therapeutics enters $100 million at-the-market stock offering agreement with Leerink Partners
FATE•Fate Therapeutics established an at-the-market program to sell up to $100 million in common stock through Leerink Partners, and terminated its previous agreement with Jefferies, which had generated $8 million in gross proceeds.
1. New offering program
Fate Therapeutics established an at-the-market offering program of up to $100 million in common stock on November 5, 2026. Leerink Partners will act as sales agent and may earn commissions of up to 3% of gross proceeds.
2. Previous agreement ended
The company terminated its previous $100 million at-the-market sales agreement with Jefferies on the same day, without termination penalties. Sales under that agreement totaled 2,801,602 shares and generated $8 million in gross proceeds.
